<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03913065</url>
  </required_header>
  <id_info>
    <org_study_id>TTM-2 CT-substudy</org_study_id>
    <nct_id>NCT03913065</nct_id>
  </id_info>
  <brief_title>Head Computed Tomography for Predicting Neurological Outcome After Cardiac Arrest</brief_title>
  <official_title>Head Computed Tomography for Predicting Neurological Outcome After Cardiac Arrest- a TTM-2 Substudy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Halmstad County Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karlstad Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Wales</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hopital Lariboisière</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Linkoeping</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The European Resuscitation Council (ERC) and the European Society of Intensive Care Medicine
      (ESICM) joint guidelines for post-resuscitation care recommend a multimodal approach to
      prognostication of neurological outcome.

      However, head computed tomography (CT) which is commonly used for predicting long-term
      neurological outcome after cardiac arrest has not yet been examined prospectively in a
      clinical trial.

      The primary purpose of the TTM-2 CT-substudy is to prospectively investigate and compare
      various methods of diagnosing generalized oedema on CT after cardiac arrest and it´s ability
      to predict long-term neurological outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a sub-study to the international multicenter Targeted Hypothermia Versus
      Targeted Normothermia After Out-of-hospital Cardiac Arrest (TTM-2) Trial (ClinicalTrials.gov
      Identifier: NCT02908308).

      All patients from participating centers still unconscious 48 hours after cardiac arrest will
      be routinely examined with CT. All other inclusion and exclusion criteria as well as
      treatment, neurological prognostication, withdrawal of life-sustaining therapy or follow-up
      will be handled according to TTM-2- protocol. Ethical approval for the main trial and this
      sub-study have been obtained from the Swedish Ethical Review Authority at Lund University
      (2015/228 and 2017/36). Both a patients´ next of kind or conscious patients have the
      opportunity to withdraw patients from the trial.

      Pseudonymized original CT images will be uploaded to a two-way secured digital platform from
      Lund University (LUSEC). Two study radiologists blinded from clinical data will perform
      analyses according to protocol. Various methods of diagnosing generalized oedema will be
      investigated including eye-balling (oedema &quot;yes&quot;/&quot;no&quot;), as well as manual and automated
      measurements of the differentiation between the grey and white matter (GWR) by placing
      circular regions of interest (ROI). Primary outcome is the neurological outcome at 6 months
      after cardiac arrest using the modified Rankin Scale (mRS).

      Secondary outcomes include neurocognitive outcomes such as the Glasgow Outcome Score-Extended
      version (GOS-E), Symbol-Digit-Modalities-Test (SDMT) and the Montreal Cognitive Assessment
      Score (MoCA).

      The results of the radiological evaluations will also be correlated with other markers of
      neuronal injury such as biomarkers, clinical neurological information or neurophysiological
      examinations.

      Additional analyses include evaluation of all available CT images of participating patients
      to investigate if there is any progression or regression of cerebral oedema.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 18, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Poor functional outcome</measure>
    <time_frame>180 days</time_frame>
    <description>Assessed using the modified Rankin Scale (mRS), with a score of 4-6 being a poor outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploratory: Neurocognitive outcome</measure>
    <time_frame>180 days</time_frame>
    <description>Montreal Cognitive Assessment Scale (MoCA), ranges from 0-30, a score above 26 is considered normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory: Neurocognitive outcome</measure>
    <time_frame>180 days</time_frame>
    <description>Symbol Digit Modalities Test (SDMT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory: Functional outcome</measure>
    <time_frame>180 days</time_frame>
    <description>Glasgow Outcome Scale-Extended version (GOS-E)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Heart Arrest, Out-Of-Hospital</condition>
  <condition>Computed Tomography</condition>
  <condition>Unconsciousness</condition>
  <condition>Neurologic Deficits</condition>
  <arm_group>
    <arm_group_label>Included patients</arm_group_label>
    <description>Cardiac arrest patients from sites participating in the TTM-2 CT-substudy still unconscious 48 hours after cardiac arrest are routinely examined with head computed tomography as soon as possible after inclusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CT</intervention_name>
    <description>Head computed tomography on patients still unconscious 48 hours after cardiac arrest.Visual evaluation of generalized oedema (&quot;eye-balling&quot;). Manual and automated measurement of the differentiation of gray and white matter (GWR) using circular regions of interest (ROI).</description>
    <arm_group_label>Included patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum samples collected in the main trial TTM-2 (ClinicalTrials.gov Identifier: NCT02908308)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with Out-of hospital cardiac arrest included in the TTM-2 trial and
        randomized to either targeted temperature management at 33°C or early treatment of fever.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Out-of-hospital cardiac arrest

          -  Presumed cardiac cause of cardiac arrest

          -  Unconscious with a FOUR-score &lt;M4 (not obeying verbal commands)

          -  Stable return of spontaneous circulation (20 min)

          -  Eligible for intensive care treatment without restrictions

          -  Inclusion within 180 minutes of ROSC

          -  Patient from participating centers, where head CT is routinely performed on all
             patients still unconscious 48 hours after cardiac arrest

        Exclusion Criteria:

          -  Unwitnessed cardiac arrest with an initial rhythm of asystole

          -  Temperature on admission &lt;30°C.

          -  Obvious or suspected pregnancy

          -  Intracranial bleeding

          -  On ECMO prior to ROSC

          -  Severe chronic obstructive pulmonary disorder (COPD) with long-term home oxygen
             therapy

          -  Patients from centers not participating in the TTM-2 CT-substudy

          -  Patients from participating centers not examined with head CT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marion Moseby-Knappe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University and Skane University Hospitals Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tobias Cronberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University and Skane University Hospitals Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marion Moseby-Knappe</name>
      <address>
        <city>Lund</city>
        <state>Skania</state>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://ttm2trial.org</url>
    <description>Website of the TTM2 trial</description>
  </link>
  <results_reference>
    <citation>Moseby-Knappe M, Pellis T, Dragancea I, Friberg H, Nielsen N, Horn J, Kuiper M, Roncarati A, Siemund R, Undén J, Cronberg T; TTM-trial investigators. Head computed tomography for prognostication of poor outcome in comatose patients after cardiac arrest and targeted temperature management. Resuscitation. 2017 Oct;119:89-94. doi: 10.1016/j.resuscitation.2017.06.027. Epub 2017 Jul 4.</citation>
    <PMID>28687281</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 5, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2019</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac arrest</keyword>
  <keyword>Hypothermia</keyword>
  <keyword>Neurological function</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Cerebral oedema</keyword>
  <keyword>Cerebral edema</keyword>
  <keyword>Cerebral ischaemia</keyword>
  <keyword>Cerebral ischemia</keyword>
  <keyword>Gray-white-matter differentiation</keyword>
  <keyword>Grey-white-matter differentiation</keyword>
  <keyword>ROI</keyword>
  <keyword>Regions of interest</keyword>
  <keyword>CT</keyword>
  <keyword>GWR</keyword>
  <keyword>Neurological prognostication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurologic Manifestations</mesh_term>
    <mesh_term>Unconsciousness</mesh_term>
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Out-of-Hospital Cardiac Arrest</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

